NCT06964737
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06964737
Title Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.